Yasir Al-Wakeel
Director/Board Member bei MAXCYTE, INC.
Vermögen: 449 933 $ am 31.03.2024
Aktive Positionen von Yasir Al-Wakeel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MAXCYTE, INC. | Director/Board Member | 15.06.2021 | - |
Independent Dir/Board Member | 15.06.2021 | - | |
VICORE PHARMA HOLDING AB | Director/Board Member | 07.05.2024 | - |
Karriereverlauf von Yasir Al-Wakeel
Ehemalige bekannte Positionen von Yasir Al-Wakeel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KRONOS BIO, INC. | Comptroller/Controller/Auditor | 01.08.2020 | 15.09.2023 |
Director of Finance/CFO | 01.08.2020 | 15.09.2023 | |
NEON THERAPEUTICS, INC. | Director of Finance/CFO | 01.06.2017 | 01.05.2020 |
MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 31.03.2017 | 01.07.2017 |
Director of Finance/CFO | 04.08.2015 | 01.07.2017 | |
Treasurer | 31.03.2017 | 01.07.2017 | |
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Analyst-Equity | 01.04.2008 | 01.06.2015 |
Ausbildung von Yasir Al-Wakeel
University of Oxford | Doctorate Degree |
University of Cambridge | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 4 |
Schweden | 2 |
Operativ
Director of Finance/CFO | 3 |
Comptroller/Controller/Auditor | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
MAXCYTE, INC. | Health Technology |
MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
VICORE PHARMA HOLDING AB | Health Technology |
KRONOS BIO, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Finance |
BioNTech US, Inc.
BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Yasir Al-Wakeel
- Erfahrung